Alkermes Plc (NASDAQ:ALKS) reported that financial results for Q3 ended Sept. 30, 2014 topped analysts' expectations, and reaffirmed its guidance for fiscal 2014 in line with Street estimates. The integrated, global biopharmaceutical company posted Q3 GAAP net loss was $40.0 million, or $0.27 loss per share, compared with the prior-year period's $7.8 million or $0.06 loss per share. Non-GAAP net income was $3.9 million, or $0.03 per share, versus $31.8 million or $0.22 per share in the same quarter the previous year. Revenue was $160 million, up from $139.8 million in the same quarter last year. Analysts polled by Capital IQ were expecting EPS of $0.02 on revenues of $155.57 million.Alkermes Plc (NASDAQ:ALKS) is updating its financial expectations for 2014 as a result of the acquisition of Civitas Therapeutics, Inc. by Acorda Therapeutics, Inc. This transaction is expected to improve GAAP net loss for ALKS by $40 million, to a range of $50 million - $70 million. GAAP loss per share is therefore expected to be $0.34 - $0.48, from the prior guidance range of $0.62 - $0.76 loss per share. ALKS continues to expect FY14 revenues to range from $580 million to $610 million, versus the Street view of $600.91 million. It also maintained its non-GAAP EPS outlook of $0.19 - $0.32, versus the consensus of $0.25 EPS. Shares are trading with a 52-week range of $34.28 - $54.25.Hershey Co (NYSE:HSY) announced Q3 results that missed analyst estimates on EPS despite revenues that were up from the same period a year ago and in line with analyst expectations. Hershey Co (NYSE:HSY) reported Q3 adjusted EPS of $1.05, up from $1.04 a year ago but missing analyst estimates of $1.09.Total revenues of $1.96 billion were up from $1.85 billion in Q3 2013 and in line with analyst projections of $1.96 billion.The company anticipates adjusted earnings per share-diluted growth for the full year to increase around 8% over the prior year, down from previous guidance projecting an increase around the low end of long-term target of 9% to 11%. The company estimates full-year 2015 net sales will increase about 7% to 9%, including the impact of foreign currency exchange rates and a contribution from acquisitions of around 2.5 points, up from previous guidance around the low end of long-term target of 5% to 7%. Shares of HSY are at $95.53 within a 52-week range of $87.88 - $108.69.Coverage of online and mobile commerce company Alibaba Group Holding Ltd (NYSE:BABA) has been initiated by analysts at RBC Capital Markets with an outperform rating. The firm set its price target on the stock at $120 a share, which represents a potential upside of 20% from its Tuesday closing price. Shares of Alibaba Group Holding Ltd (NYSE:BABA) were up 0.28% to $99.96, moving within a 52-week trading range of $82.81 - $100.67.
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
